

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
14 September 2023 (14.09.2023)



(10) International Publication Number  
**WO 2023/170550 A1**

(51) International Patent Classification:

A61K 31/40 (2006.01) A61K 45/06 (2006.01)  
A61K 9/00 (2006.01) A61P 25/24 (2006.01)

(21) International Application Number:

PCT/IB2023/052088

(22) International Filing Date:

06 March 2023 (06.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/317,475 07 March 2022 (07.03.2022) US

(71) Applicant: **JANSSEN PHARMACEUTICALS, INC.**  
[US/US]; 1125 Trenton-Harbourton Road, Titusville, New  
Jersey 08560 (US).

(72) Inventors: **FERNANDES, Philippe**; Janssen Pharmaceu-  
tica NV, Turnhoutseweg 30, 2340 Beerse (BE). **SCH-  
MIDT, Mark**; Janssen Pharmaceutica NV, Turnhoutseweg  
30, 2340 Beerse (BE). **POPOVA, Vanina**; Janssen Phar-

maceutica NV, Turnhoutseweg 30, 2340 Beerse (BE).  
**SAVITZ, Adam**; Janssen Pharmaceutica NV, Turnhout-  
seweg 30, 2340 Beerse (BE). **MELKOTE, Rama**; Janssen  
Research & Development, LLC, 920 US Route 202, PO  
Box 300, Raritan, New Jersey 08869 (US). **DREVETS,  
Wayne C.**; Janssen Research & Development, LLC, 920 US  
Route 202, PO Box 300, Raritan, New Jersey 08869 (US).  
**GOPAL, Srihari**; Janssen Research & Development, LLC,  
920 US Route 202, PO Box 300, Raritan, New Jersey 08869  
(US). **PEMBERTON, Darrel**; Janssen Pharmaceutica NV,  
Turnhoutseweg 30, 2340 Beerse (BE). **LAGISHETTY,  
Chakradhar**; Janssen Research & Development, LLC, 920  
US Route 202, PO Box 300, Raritan, New Jersey 08869  
(US). **KEZIC, Iva**; Janssen Pharmaceutica NV, Turnhout-  
seweg 30, 2340 Beerse (BE).

(74) Agent: **LANE, David A.** et al.; JOHNSON & JOHNSON,  
One Johnson & Johnson Plaza, New Brunswick, New Jersey  
08933 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,

(54) Title: POLYMORPH FORMS OF ATICAPRANT FOR USE IN TREATING MAJOR DEPRESSIVE DISORDER




Fig. 1

(57) Abstract: The disclosure provides crystalline and amorphous forms of aticaprant. Also provided by the disclosure are pharmaceu-  
tical compositions comprising the amorphous or crystalline forms, methods of treating major depressive disorder using the amorphous  
or crystalline forms of aticaprant, amorphous or crystalline forms of aticaprant for use in the treatment of major depressive disorder in  
a human patient having anhedonia, uses of the amorphous or crystalline forms of aticaprant in the manufacture of a medicament for  
the treatment of major depressive disorder, and packages or pharmaceutical products comprising (i) amorphous or crystalline forms of  
aticaprant and (ii) instructions for treating major depressive disorder. In some aspects, the human patient treated as described herein  
has anhedonia.

[Continued on next page]

WO 2023/170550 A1

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*